Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31420819 | 0.86 | ALDH1A1 (0.39) | ALDH1A1GFERMEN1KMT2ATDP1 | |
| SCHEMBL2084230 | 0.84 | ALDH1A1 (0.48) | ALDH1A1GFERHTTNPSR1MEN1 | |
| SCHEMBL6172065 | 0.82 | GPR119 (0.35) | ALDH1A1TDP1 | |
| SCHEMBL27746941 | 0.82 | CYP2C9 (0.47) | TDP1NAMPT | |
| SCHEMBL28861530 | 0.82 | CPB2 (0.45) | ALDH1A1GFERHTTNPSR1MEN1 | |
| SCHEMBL14468493 | 0.81 | NPC1 (0.33) | ALDH1A1MEN1KMT2APOLBMAPT | |
| SCHEMBL2328448 | 0.81 | ALDH1A1 (0.44) | ALDH1A1GFERHTTNPSR1TDP1 | |
| SCHEMBL2470563 | 0.80 | NR1H2 (0.38) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL2219479 | 0.80 | NR1H2 (0.38) | TDP1 | |
| SCHEMBL18950459 | 0.79 | GPR119 (0.36) | HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557989-B2 | Electrochemical affinity biosensor system and methods | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130213822-A1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8293904-B2 | Electrochemical affinity biosensor system and methods | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8288544-B2 | Electrochemical affinity biosensor system and methods | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-1646637-B1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS GMBH (DE) | 2012-08-15 | — | — | EP | disclosed |
| EP-1646637-B1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS GMBH (DE) | 2012-08-15 | — | — | EP | disclosed |
| EP-2465862-A1 | Mononuclear osmium complexes for use in biosensors | Roche Diagniostics GmbH (DE) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465862-A1 | Mononuclear osmium complexes for use in biosensors | Roche Diagniostics GmbH (DE) | 2012-06-20 | — | — | EP | disclosed |
| US-20120125788-A1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2012-05-24 | — | — | US | disclosed |
| WO-2011088075-A2 | NOVEL SALTS, POLYMORPHS, AND SYNTHETIC PROCESSES REGARDING IMIDAZOLE DERIVATIVE | ORE PHARMACEUTICALS INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2005026178-A2 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS GMBH (DE) | 2005-03-24 | — | — | WO | disclosed |
| WO-2001017992-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| CN-1039323-C | Imidazopyriding derivatives and process for preparation thereof | TANABE SEIYAKU CO (JP) | 1998-07-29 | — | — | CN | disclosed |
| EP-0531876-B1 | Imidazoindolizine derivatives and process for preparation thereof | TANABE SEIYAKU CO (JP) | 1996-12-18 | — | — | EP | disclosed |
| US-5510354-A | HYPOTENSIVE AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1996-04-23 | — | — | US | disclosed |
| US-5424316-A | Imidazopyridine derivatives for the treatment of hypertension | TANABE SEIYAKU CO., LTD. (JP) | 1995-06-13 | — | — | US | disclosed |
| US-5409936-A | Useful in prophylaxix; exhibits potent angiotensin ii inhibitory acivities | TANABE SEIYAKU CO., LTD. (JP) | 1995-04-25 | — | — | US | disclosed |
| US-5268377-A | Imidazoindolizine derivatives process for preparation thereof and use thereof to treat hypertension | TANABE SEIYAKU CO., LTD. (JP) | 1993-12-07 | — | — | US | disclosed |
| EP-0531876-A2 | Imidazoindolizine derivatives and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
| EP-0531874-A1 | Imidazopyridine derivatives and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130213822-A1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | SIGLEC7, FCGR3B, FCER2 | ALDH1A1 1343/4885GFER 1404/4885HTT 4827/4885 |
| US-20120125788-A1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | SIGLEC7, FCGR3B, FCER2 | ALDH1A1 1343/4885GFER 1404/4885HTT 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.